JP2016516403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516403A5 JP2016516403A5 JP2015562411A JP2015562411A JP2016516403A5 JP 2016516403 A5 JP2016516403 A5 JP 2016516403A5 JP 2015562411 A JP2015562411 A JP 2015562411A JP 2015562411 A JP2015562411 A JP 2015562411A JP 2016516403 A5 JP2016516403 A5 JP 2016516403A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- interest
- amplification
- expression level
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801718P | 2013-03-15 | 2013-03-15 | |
| US61/801,718 | 2013-03-15 | ||
| PCT/IB2014/001253 WO2014140933A2 (en) | 2013-03-15 | 2014-03-14 | Method for the prognosis and treatment of cancer metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516403A JP2016516403A (ja) | 2016-06-09 |
| JP2016516403A5 true JP2016516403A5 (enExample) | 2017-11-16 |
| JP6577873B2 JP6577873B2 (ja) | 2019-09-18 |
Family
ID=51265712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562411A Active JP6577873B2 (ja) | 2013-03-15 | 2014-03-14 | がんの転移の予後診断および処置のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160032400A1 (enExample) |
| EP (1) | EP2971113B1 (enExample) |
| JP (1) | JP6577873B2 (enExample) |
| KR (1) | KR20150122731A (enExample) |
| CN (1) | CN105324491B (enExample) |
| AU (1) | AU2014229505B2 (enExample) |
| BR (1) | BR112015023783A2 (enExample) |
| CA (1) | CA2906394A1 (enExample) |
| MX (2) | MX2015011362A (enExample) |
| WO (1) | WO2014140933A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| CA2725978A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| US8669057B2 (en) | 2009-05-07 | 2014-03-11 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| DK3091085T3 (da) | 2010-10-06 | 2019-05-06 | Inst Catalana Recerca Estudis Avancats | Fremgangsmåde til at designe en terapi mod brystcancermetastase |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| US10513737B2 (en) | 2011-12-13 | 2019-12-24 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) * | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| ES3015226T3 (en) | 2012-08-16 | 2025-04-30 | Veracyte Sd Inc | Prostate cancer prognosis using biomarkers |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| ES2906586T3 (es) | 2012-10-12 | 2022-04-19 | Inbiomotion Sl | Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata |
| WO2014186036A1 (en) | 2013-03-14 | 2014-11-20 | Allegro Diagnostics Corp. | Methods for evaluating copd status |
| WO2014140896A2 (es) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| CN114606309A (zh) | 2014-11-05 | 2022-06-10 | 威拉赛特公司 | 使用机器学习和高维转录数据的诊断系统和方法 |
| EP3229909B1 (en) | 2014-12-11 | 2020-10-14 | Inbiomotion S.L. | Binding members for human c-maf |
| US20210299267A1 (en) * | 2016-02-18 | 2021-09-30 | Kyoto University | Complex capable of inhibiting genetic function in exosome, and cancer proliferation and/or metastasis suppressor |
| EP3439640B1 (en) * | 2016-04-08 | 2024-01-17 | The Cleveland Clinic Foundation | Nanoparticles for drug delivery to treat bone disease |
| US20190218302A1 (en) * | 2016-05-19 | 2019-07-18 | Probiocon Gmbh | Anti-cancer combination treatment |
| MX2018014279A (es) * | 2016-05-25 | 2019-07-08 | Inbiomotion Sl | Tratamiento terapeutico de cancer de mama con base en estado de c-maf. |
| EP3484487A4 (en) * | 2016-07-12 | 2020-06-17 | The University of North Carolina at Chapel Hill | BIOMATRIX SCALES FOR USE IN THE DIAGNOSIS AND MODELING OF CANCER |
| US11414708B2 (en) | 2016-08-24 | 2022-08-16 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| AU2018210695B2 (en) | 2017-01-20 | 2024-07-18 | The University Of British Columbia | Molecular subtyping, prognosis, and treatment of bladder cancer |
| WO2018165600A1 (en) | 2017-03-09 | 2018-09-13 | Genomedx Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| US11078542B2 (en) | 2017-05-12 | 2021-08-03 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| AU2018310987A1 (en) | 2017-08-04 | 2020-02-27 | Decipher Biosciences, Inc. | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy |
| US11654153B2 (en) | 2017-11-22 | 2023-05-23 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
| CN108084254A (zh) * | 2017-11-30 | 2018-05-29 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的抗癌基因WWOXδ6-8突变蛋白及其应用 |
| WO2021185959A1 (en) * | 2020-03-19 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Estrogen-related receptor alpha agonists for the treatment and the prognosis of bone metastases |
| CN115198013A (zh) * | 2021-04-14 | 2022-10-18 | 迪瑞药业(成都)有限公司 | 用以鉴别出适用精氨酸剥夺疗法的患者的方法与试剂盒 |
| WO2024168138A2 (en) * | 2023-02-08 | 2024-08-15 | Iogenetics, Llc | Expedited neoantigen vaccines |
| CN115919464B (zh) * | 2023-03-02 | 2023-06-23 | 四川爱麓智能科技有限公司 | 肿瘤定位方法、系统、装置及肿瘤发展预测方法 |
| CN119614707A (zh) * | 2025-01-13 | 2025-03-14 | 中山大学 | ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE89314T1 (de) | 1985-02-13 | 1993-05-15 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| EP0910652B1 (en) | 1996-04-05 | 2014-10-08 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| PT951551E (pt) | 1996-12-23 | 2008-10-28 | Immunex Corp | Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| EA200100972A1 (ru) | 1999-03-15 | 2002-02-28 | Аксис Фармасьютикалз, Инк. | Новые соединения и композиции как ингибиторы протеаз |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| JP2003525874A (ja) | 2000-01-06 | 2003-09-02 | メルク フロスト カナダ アンド カンパニー | プロテアーゼ阻害剤としての新規化合物および組成物 |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| CA2451955C (en) | 2001-06-26 | 2015-09-29 | Abgenix, Inc. | Antibodies to opgl |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| AU2003903540A0 (en) | 2003-07-09 | 2003-07-24 | Atdec Pty Ltd | Flat panel display wall mounting system |
| US20050060771A1 (en) | 2003-09-11 | 2005-03-17 | Farmer Andrew Alan | siRNA encoding constructs and methods for using the same |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| WO2006012221A2 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Target cell-specific short interfering rna and methods of use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US8242081B2 (en) | 2005-12-06 | 2012-08-14 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP1984024A2 (en) * | 2006-01-05 | 2008-10-29 | Novartis AG | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| KR101264473B1 (ko) | 2007-05-24 | 2013-05-29 | 아블린쓰 엔.브이. | Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드 |
| WO2010000796A1 (en) * | 2008-07-02 | 2010-01-07 | Assistance Publique - Hôpitaux De Paris | A method for predicting clinical outcome of patients with non-small cell lung carcinoma |
| DK3091085T3 (da) * | 2010-10-06 | 2019-05-06 | Inst Catalana Recerca Estudis Avancats | Fremgangsmåde til at designe en terapi mod brystcancermetastase |
| WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) * | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
-
2014
- 2014-03-14 KR KR1020157026432A patent/KR20150122731A/ko not_active Ceased
- 2014-03-14 MX MX2015011362A patent/MX2015011362A/es unknown
- 2014-03-14 US US14/776,412 patent/US20160032400A1/en not_active Abandoned
- 2014-03-14 CN CN201480015564.0A patent/CN105324491B/zh active Active
- 2014-03-14 CA CA2906394A patent/CA2906394A1/en active Pending
- 2014-03-14 BR BR112015023783A patent/BR112015023783A2/pt not_active Application Discontinuation
- 2014-03-14 WO PCT/IB2014/001253 patent/WO2014140933A2/en not_active Ceased
- 2014-03-14 EP EP14747411.8A patent/EP2971113B1/en active Active
- 2014-03-14 AU AU2014229505A patent/AU2014229505B2/en active Active
- 2014-03-14 JP JP2015562411A patent/JP6577873B2/ja active Active
-
2015
- 2015-09-02 MX MX2020001156A patent/MX2020001156A/es unknown
-
2021
- 2021-04-27 US US17/241,571 patent/US20210317534A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539625A5 (enExample) | ||
| JP2016105731A5 (enExample) | ||
| JP2018078911A5 (enExample) | ||
| Huang et al. | Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model | |
| JP2015521050A5 (enExample) | ||
| Lee et al. | Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma | |
| JP2022125079A (ja) | がん転移の予後診断および処置のための方法 | |
| WO2013182912A4 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| Tobin et al. | The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer | |
| CN105324491B (zh) | 用于癌症转移的诊断和治疗的方法 | |
| JP6735277B2 (ja) | 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 | |
| JP2019523641A5 (enExample) | ||
| JP2013541339A5 (enExample) | ||
| KR20120047912A (ko) | 암 요법에서 항ｅｇｆｒ 항체의 효능을 결정하기 위한 바이오마커 및 방법 | |
| Berezowska et al. | Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas | |
| JP6603474B2 (ja) | 癌治療 | |
| CN105980576A (zh) | 用于源自乳腺癌的骨转移癌的预后和治疗的方法 | |
| Charafe-Jauffret et al. | Defining the molecular biology of inflammatory breast cancer | |
| Zhang et al. | Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis | |
| JP7235508B2 (ja) | Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法 | |
| CN105765081A (zh) | 一种用于预测对采用egfr抑制剂的治疗的响应性的方法 | |
| EP2935620A1 (en) | Prediction of the treatment response to an anti-egfr molecule in colorectal cancer patients | |
| WO2016104794A1 (ja) | Ｂｒａｆ変異検出によるｅｇｆｒ阻害剤の効果予測 | |
| KR20240157611A (ko) | 전이성 유방암의 항암제 치료 반응성 및 예후 예측용 신규한 바이오마커 및 이의 용도 | |
| Stickeler | Prognostic and predictive markers for treatment decisions in early breast cancer |